Novartis (NYSE:NVS) Withdraws Application For Amgen Biosimilar Candidate From EMA

Novartis (NYSE:NVS) Withdraws Application For Amgen Biosimilar Candidate From EMA

In the last summer, Novartis (NYSE:NVS) did not make much ho-hum about the fact that its application for the doppelganger drug of Neulasta (pegfilgrastim) was rejected by the U.S. FDA. However, in a latest bid, the company’s hope from the EU also crashed. In a recent update, the drug approval body of EMA or European Medicine Agency, CHMP (Committee for Medicinal Products for Human Use) told about withdraw of the […]

Read More ˃